047 – Sarepta Receives CRL for Golodirsen! IOVA impresses in solid tumors.

In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I also take a close look at Iovance Biotherapeutics and their tumor infiltrating lymphocyte cell therapy for cancer treatment.

this is not investment advice



Leave a Reply

%d bloggers like this: